Verrica Pharmaceuticals (NASDAQ:VRCA) Issues Quarterly Earnings Results

Verrica Pharmaceuticals (NASDAQ:VRCA) posted its earnings results on Monday. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12), Zacks reports. Verrica Pharmaceuticals had a negative return on equity of 3,102.90% and a negative net margin of 625.06%. The company had revenue of ($1.78) million during the quarter, compared to analysts’ expectations of $7.53 million.

Verrica Pharmaceuticals Stock Down 2.8 %

Verrica Pharmaceuticals stock traded down $0.02 during trading hours on Thursday, hitting $0.73. The stock had a trading volume of 420,983 shares, compared to its average volume of 454,597. The stock’s 50-day moving average price is $1.64 and its 200-day moving average price is $5.14. Verrica Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $11.41. The company has a quick ratio of 2.23, a current ratio of 2.36 and a debt-to-equity ratio of 29.58. The stock has a market capitalization of $30.96 million, a P/E ratio of -0.41 and a beta of 1.45.

Analyst Upgrades and Downgrades

VRCA has been the subject of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $11.00 to $2.00 in a research report on Tuesday. TD Cowen cut their price objective on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, October 21st. Finally, HC Wainwright lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.60.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.